EIB signs a EUR 25 million ‘quasi-equity’ financing deal with podcast company Acast for R&D and international expansion
Agreement supported by Juncker Plan’s European Fund for Strategic Investments
The European Investment Bank (EIB) has signed a EUR 25 million quasi-equity financing agreement with podcast company Acast. As well as independent podcasts, Acast also looks after the audio content of larger publishers, such as the Financial Times, the Guardian, Vogue, Aftonbladet and Billboard. The EIB financing is supported by theEuropean Fund for Strategic Investments (EFSI), the main pillar of theInvestment Plan for Europe, or Juncker Plan.
Acast will use the financing to expand its research and development activities and to further develop its audio content distribution platform. The company is headquartered in Sweden and its services are available in 10 countries. A part of the project costs will go into supporting its international market expansion. The peculiarity of the‘quasi equity’ financing, which the EIB is only able to support with the backing of the Juncker Plan, is that it has the characteristics of an equity stake in the company, yet does not translate into the EIB owning shares in Acast. This type of financing addresses a market failure for non-dilutive growth capital for European businesses: providing equity without affecting the ownership of the company.
European Commission Vice-President Valdis Dombrovskis, responsible for the Euro and Social Dialogue, also in charge of Financial Stability, Financial Services and Capital Markets Union, said: “The main motivation for creating the Juncker Plan was to provide alternative sources of financing to innovative companies in need of financial support that struggled to obtain a traditional bank loan, and as a result to boost jobs, growth and investment in the EU. Today’s agreement between the EIB and Acast does exactly that, and it does so using a novel form of financing. I wish the company every success with its expansion plans.”
“The EIB’s investment and support of Acast is a true milestone in our company's growth as well as in the future of the global podcasting infrastructure. Today, we are one step closer to our goal of seeking out and supporting all the audio storytellers of the world - giving their stories the audience they deserve,” said Leandro Saucedo, Chief Business Officer of Acast.
EIB Vice-President Alexander Stubb, added: “Everyone loves a good podcast, but it can be hard to make a living off of this type of infotainment. I think it’s important that a European provider for this type of service exists, which gives all voices the possibility to be heard. Acast truly serves as a one-stop-shop for listeners, creators and advertisers, and we’re happy to support the company in its expansion.”
The Italian Ministry of Defence has now joined the list of beneficiaries of the EU bank’s financing. This innovative EU financing operation totalling €220 million was signed between the EIB, the Ministry of Economy and Finance (MEF) and the Ministry of Defence to support the construction of three navy vessels, which will be used by the Italian Navy’s Hydrographic Institute (IIM) based in Genoa.
The EIB will provide up to €20 million to finance the research, development and innovation (RDI) strategy of PROSOL, a family business that manufactures and distributes coffee products such as instant (soluble) coffee and single-serving products (capsules). This financing comes under the European Fund for Strategic Investments, which enables the EIB Group to offer increased support for investments fostering innovation, economic growth and employment.
The EIB and Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the signing of a €24.5 million financing agreement. The venture loan is intended to support Immunic’s ongoing phase 2 CALVID-1 trial of its lead asset, IMU-838, in patients with moderate coronavirus disease 2019 (COVID-19). In addition, it is also intended to support the potential expansion of the CALVID-1 trial into a confirmatory phase 3 trial and the commercial-scale manufacturing for IMU-838. Immunic AG, the German subsidiary of Immunic, Inc., will receive the EIB loan in three tranches upon the completion of pre-defined milestones.